Researchers test drug combinations to prevent graft vs. host disease

June 26, 2012

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

The study randomized 74 patients, ages 16 to 70, to receive either SIR/TAC or MTX/TAC. Patients were stratified by donor relation (siblings or matched, unrelated individuals) and age.

Their study was published in a recent issue of Haematologica, the journal of the European Hematology Association.

"Graft vs. host disease poses major health problems for patients who have received hematopoietic and threatens the long-term success of their transplant," said Joseph Pidala, M.D., M.S., a medical oncologist and study principal investigator. "Existing pharmacologic strategies do not adequately prevent acute graft vs. host disease following allogeneic hematopoietic (blood) , and effective acute GVHD prevention is an important clinical goal necessary to ensure the long-term success of transplantation."

According to the authors, their study design mandated at least one year of sirolimus therapy in order to both limit the risk from chronic GVHD development and to promote the patients' based on the "reconstitution" of the patients' immune cells, called regulatory T cells, or "Tregs."

"Our hypothesis was that SIR-based would suppress alloreactive T cells, support the recovery of the immune system's Tregs, and more effectively prevent GVHD," explained Pidala.

Results showed that on days 30 and 90 post transplantation, SIR/TAC-treated patients had "a significantly greater proportion of among the CD 4 in their peripheral blood" and their regulatory Tregs were "functional."

The authors suggested that the "net benefit" observed in Treg reconstitution with SIR/TAC-treated patients was likely due to both the suppression of immune systems' non-Treg CD4 T cells by sirolimus, as well as the lower tacrolimus exposure for these patients as compared to patients on the MTX/TAC arm of the study.

Explore further: Researchers find regulatory T-cell clue to help prevent GVHD

Related Stories

Researchers find regulatory T-cell clue to help prevent GVHD

October 31, 2011
Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important ...

Mini-molecule governs severity of acute graft vs. host disease, study finds

March 12, 2012
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.

Best post-transplant drug regimen identified for patients with new kidneys

July 29, 2011
For the thousands of patients who receive kidney transplants in the United States each year, preventing organ rejection without compromising other aspects of health requires a delicate balance of medications. Immunosuppresive ...

HIV drug reduces graft-versus-host disease in stem cell transplant patients

December 13, 2011
An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according ...

Recommended for you

Drug blocks Zika, other mosquito-borne viruses in cell cultures

December 12, 2017
If there was a Mafia crime family of the virus world, it might be flaviviruses.

Study seeks to aid diagnosis, management of catatonia

December 11, 2017
Catatonia, a syndrome of motor, emotional and behavioral abnormalities frequently characterized by muscular rigidity and a trance-like mental stupor and at times manifesting with great excitement or agitation, can occur during ...

New compound stops progressive kidney disease in its tracks

December 7, 2017
Progressive kidney diseases, whether caused by obesity, hypertension, diabetes, or rare genetic mutations, often have the same outcome: The cells responsible for filtering the blood are destroyed. Reporting today in Science, ...

New Lyme disease tests could offer quicker, more accurate detection

December 7, 2017
New tests to detect early Lyme disease - which is increasing beyond the summer months -could replace existing tests that often do not clearly identify the infection before health problems occur.

Spinal tap needle type impacts the risk of complications

December 6, 2017
The type of needle used during a lumbar puncture makes a significant difference in the subsequent occurrence of headache, nerve irritation and hearing disturbance in patients, according to a study by Hamilton medical researchers.

Men with HPV are 20 times more likely to be reinfected after one year

December 5, 2017
A new analysis of genital human papillomavirus (HPV) in men shows that infection with one HPV type strongly increases the risk of reinfection with the same type. In fact, men who are infected with the type responsible for ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.